跳至主要内容
临床试验/NCT04102033
NCT04102033Unknown4 期

Efficacy of Eltrombopag in Chronic Immune Thrombocytopenia in Pediatrics

Assiut University0 个研究点目标入组 20 人开始时间: 2019年11月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
入组人数
20
主要终点
Measuring the platelet count response to eltrombopag in pediatric chronic ITP

研究概览

简要总结

This study aims to evaluate the efficacy of eltrombopag on the platelet count in pediatric patients with chronic immune thrombocytopenia.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
1 Year 至 17 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Pediatric patients with chronic ITP aged 1 to 17 years.
  • Platelet count is less than 30×109 per liter.
  • Patients neither have had spontaneous resolution of the thrombocytopenia nor responded to corticosteroids and/or IV immunoglobulin.

排除标准

  • Patients with clinical and/or laboratory evidence of hepatotoxicity/liver decompensation (Hepatotoxicity due to eltrombopag is defined as increased serum alanine aminotransferase ≥3 times the upper limit of normal (ULN), aspartate aminotransferase ≥3 ULN, alkaline phosphatase >1.5 ULN, total bilirubin >1.5 ULN)
  • Patients with history of thrombotic/thromboembolic events.

结局指标

主要结局

Measuring the platelet count response to eltrombopag in pediatric chronic ITP

时间窗: 6 months

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

GM Abdelsalam

doctor

Assiut University

相似试验